Posting of Annual Report& Accounts & Notice of AGM

RNS Number : 2840Z
Surgical Innovations Group PLC
21 May 2021


Surgical Innovations Group plc

("Surgical Innovations", "SI" or the "Company")


Posting of Annual Report & Accounts

Notice of Annual General Meeting


Surgical Innovations Group plc (AIM: SUN), the designer, manufacturer and distributor of innovative medical technology for minimally invasive surgery ("MIS"), confirms that the Annual Report and Accounts for the year ended 31 December 2020 ("2020 Annual Report") and the Notice of the 2021 Annual General Meeting ("AGM") have now been published and can be accessed via the "Investor Centre" section of the Company's website at:


The 2020 Annual Report, the Notice of AGM and details voting by proxy will be posted to shareholders who have not consented to receive electronic communications.


Notice of AGM

The AGM is to be held on 22 June 2021 at 12:00 noon at the Company's offices at Clayton Wood House, 6 Clayton Wood Bank, Leeds, LS16 6QZ and will consider the Resolutions set out in the Notice of AGM.


Currently, COVID-19 restrictions and guidance are in place which prevent us convening the AGM in the usual way. The Board are hopeful that such Government guidance and restrictions may be relaxed further prior to the AGM, but we will continue to follow Government guidance. We recognise that the AGM is an important event for shareholders and the Company is keen to ensure that shareholders are able to exercise their right to vote and participate at this year's AGM.


Shareholders wishing to attend the meeting in person should pre-register their desired attendance by emailing , titled 'AGM' no later than 12 noon on Friday 18 June 2021. We urge individuals to continue to monitor guidance and/or directions issued by the UK Government on COVID-19 and to act accordingly.


Whilst we currently plan on holding the AGM at our Clayton Wood House, 6 Clayton Wood Bank, Leeds office in a COVID-19 secure manner, it is possible that the evolving COVID-19 pandemic and Government restrictions and guidance in response to any developments may mean that this is not possible. Accordingly, the Board strongly encourages Shareholders to vote by proxy on the resolutions contained in the Notice of AGM.


If it is not possible to attend the AGM this year, we will provide an opportunity for shareholder engagement prior to the AGM. In order to facilitate this, if you are a shareholder and would like to ask the Board a question, please submit your questions to the following email: , titled 'AGM'. Shareholders should note that any questions in relation to confidential or potentially price sensitive matters will not be addressed, nor will those for which the answer is already publicly available.


The Board will keep the situation under review and may need to make further changes to the arrangements relating to the AGM, including how it is conducted, and Shareholders should therefore continue to monitor the Company's website for any updated announcements.


As the AGM will be held as outlined above, you should vote on the proposed resolutions by appointing a proxy. The proxy appointment form should be returned, or the electronic proxy appointment instruction transmitted, no later than 12:00 noon on Friday 18 June 2021. More details can be found in the Notice of AGM.




For further information please contact:

Surgical Innovations Group plc

www sigroupplc com

David Marsh, CEO

Tel: 0113 230 7597

Charmaine Day, Co Sec & GFC

N+1 Singer (Nominated Adviser & Broker)

Tel: 020 7496 3000

Aubrey Powell / Rachel Hayes/ Iqra Amin

Walbrook PR (Financial PR & Investor Relations)

Tel: 020 7933 8780 or

Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / 07584 391 303



About Surgical Innovations Group plc

The Group specialises in the design, manufacture, sale and distribution of innovative, high quality medical products, primarily for use in minimally invasive surgery. Our product and business development is guided and supported by a key group of nationally and internationally renowned surgeons across the spectrum of minimally invasive surgical activity.


We design and manufacture and source our branded port access systems, surgical instruments and retraction devices which are sold directly in the UK home market through our subsidiary, Elemental Healthcare, and exported widely through a global network of trusted distribution partners. Many of our products in this field are based on a "resposable" concept, in which the products are part re-usable, part disposable, offering a high quality and environmentally responsible solution at a cost that is competitive against fully disposable alternatives.


Elemental also has exclusive UK distribution for a select group of specialist products employed in laparoscopy, bariatric and metabolic surgery, hernia repair and breast reconstruction.

In addition, we design and develop medical devices for carefully selected OEM partners, and have also collaborated with a major UK industrial partner to provide precision engineering solutions to complex problems outside the medical arena.


We aim for our brands to be recognised and respected by healthcare professionals in all major geographical markets in which we operate and provide by development, partnership or acquisition a broad portfolio of cost effective, procedure specific surgical instruments and implantable devices that offer reliable solutions to genuine clinical needs in the operating theatre environment.


The Group currently employs approximately 100 people across two sites in the UK. Product design, engineering and manufacturing are carried out at the SI site in Yorkshire. Commercial activities including marketing, UK distribution and international sales and marketing are based at Elemental Healthcare in Berkshire.


Further information


Further details of the Group's businesses and products are available on the following websites:


www sigroupplc com

www surginno com

www elementalhealthcare


To receive regular updates by email, please contact

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
UK 100